Checkpoint Therapeutics Inc CKPT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CKPT is a good fit for your portfolio.
News
-
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CKPT
-
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Checkpoint Therapeutics, Inc. (CKPT)
-
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Checkpoint Therapeutics, Inc. (CKPT)
-
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint
-
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CKPT
-
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Checkpoint Therapeutics, Inc. (CKPT) Investors
-
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, Checkpoint, and Sonder and Encourages Investors to Contact the Firm
Trading Information
- Previous Close Price
- $1.60
- Day Range
- $1.45–1.68
- 52-Week Range
- $1.30–3.62
- Bid/Ask
- $1.48 / $1.51
- Market Cap
- $52.10 Mil
- Volume/Avg
- 755,254 / 436,455
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 291.12
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 23
- Website
- https://www.checkpointtx.com
Valuation
|
Metric
|
CKPT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 291.12 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CKPT
|
|---|---|
Quick Ratio | 0.27 |
Current Ratio | 0.29 |
Interest Coverage | — |
Quick Ratio
CKPT
Profitability
|
Metric
|
CKPT
|
|---|---|
Return on Assets (Normalized) | −699.99% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
CKPT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Pqfdgkfl | Wpwz | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wclzfxhz | Dgjhzq | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jdgzvspl | Cnnjqm | $98.1 Bil | |
MRNA
| Moderna Inc | Pfddfvkdk | Dxlry | $39.1 Bil | |
ARGX
| argenx SE ADR | Dlvkmpcf | Mxf | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Dzbzgscqc | Czt | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rglgzhgzm | Yfcmng | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hwtxfcw | Xxqkkxl | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qrlwnccft | Dtxfnj | $12.5 Bil | |
INCY
| Incyte Corp | Yszkqpfhm | Qqjvgm | $11.9 Bil |